Overview

Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis

Status:
Not yet recruiting
Trial end date:
2027-02-02
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of IV antifrolumab in adult patients with Active Proliferative Lupus Nephritis
Phase:
Phase 3
Details
Lead Sponsor:
AstraZeneca